zack geeft een strong buy af
hier een artikel van half juli
ProNAi Therapeutics Inc. (NASDAQ:DNAI) has received an average broker rating score of 2.50 (Hold) from the four analysts that provide coverage for the company, Zacks Investment Research reports. Three equities research analysts have rated the stock with a hold rating and one has issued a strong buy rating on the company. ProNAi Therapeutics’ rating score has declined by 150% from 90 days ago as a result of various analysts’ upgrades and downgrades.
Brokerages have set a 1 year consensus target price of $3.75 for the company and are predicting that the company will post ($0.38) EPS for the current quarter, according to Zacks. Zacks has also assigned ProNAi Therapeutics an industry rank of 108 out of 265 based on the ratings given to related companies.
An institutional investor recently bought a new position in ProNAi Therapeutics stock. Jennison Associates purchased a new position in ProNAi Therapeutics Inc. (NASDAQ:DNAI) during the third quarter, according to its most recent filing with the SEC. The institutional investor purchased 150,381 shares of the company’s stock, valued at approximately $3,086,000. Jennison Associates owned about 0.50% of ProNAi Therapeutics as of its most recent filing with the SEC.
Shares of ProNAi Therapeutics (NASDAQ:DNAI) traded down 1.49% on Thursday, reaching $1.98. 131,019 shares of the company’s stock traded hands. ProNAi Therapeutics has a 12-month low of $1.85 and a 12-month high of $33.75. The company’s market cap is $59.74 million. The stock has a 50-day moving average price of $2.89 and a 200-day moving average price of $6.32.
ProNAi Therapeutics (NASDAQ:DNAI) last announced its earnings results on Tuesday, May 10th. The company reported ($0.35) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.42) by $0.07. Equities research analysts anticipate that ProNAi Therapeutics will post ($1.33) EPS for the current fiscal year.
Several equities research analysts have recently weighed in on the stock. Jefferies Group reissued a “buy” rating on shares of ProNAi Therapeutics in a research note on Sunday, May 29th. Zacks Investment Research downgraded shares of ProNAi Therapeutics from a “buy” rating to a “hold” rating in a research note on Wednesday, May 4th. Wedbush downgraded shares of ProNAi Therapeutics from an “outperform” rating to a “neutral” rating in a research note on Monday, June 6th. Finally, SunTrust Banks Inc. downgraded shares of ProNAi Therapeutics from a “buy” rating to a “neutral” rating and reduced their target price for the company from $25.00 to $4.00 in a research note on Monday, June 6th.
ProNAi Therapeutics, Inc is a clinical-stage oncology company. The Company is engaged in business of researching, developing and commercializing therapies for the treatment of patients with cancer and hematological diseases based on its deoxyribonucleic acid interference (DNAi) technology platform. Its lead product candidate includes PNT2258, which targets cancers that overexpress B-cell lymphoma 2 (BCL2), an oncogene known to be dysregulated in various types of cancer.